Anadex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anadex

Property Description
Active ingredient Anastrozole
Form Oral Tablet
Pharmacological class Aromatase Inhibitor, Antineoplastic Agent
General purpose Suppression of circulating estrogen levels
Origin Synthetic, Non-steroidal compound

Anadex: Identity and Pharmacological Classification

Anadex is a prescription-only medication whose active ingredient is the chemical substance Anastrozole. It is formally classified as an antineoplastic agent and is specifically categorized as an aromatase inhibitor. Anadex’s defining feature is its classification as a potent, third-generation agent within this class, an attribute clinically recognized for its specific inhibitory activity. The drug is a form of targeted therapy used as a hormone antagonist, designed to intervene precisely in hormonal production. Anastrozole works by blocking the enzyme responsible for estrogen production, a common mechanism in managing certain hormone-sensitive conditions.

Composition, Origin, and Form

The drug’s structure confirms its synthetic nature; Anastrozole is defined as a non-steroidal compound and a triazole derivative. Anadex is commercially prepared as an oral medication, typically formulated as a tablet, which constitutes its dosage form. This simple form is combined with essential solid pharmaceutical excipients and is intended for the non-invasive oral route of administration. Anastrozole effectively lowers the body’s total amount of estrogen.

The General Purpose of Aromatase Inhibition

The fundamental purpose of Anadex is to achieve the significant suppression of circulating estrogen levels in the body. It operates by competitively and selectively binding to the aromatase enzyme, thereby causing efficient aromatase enzyme blockage. This action stops the final step in the biosynthesis of estrogen from androgen precursors, which is the primary source of this steroid hormone in postmenopausal women. A typical use scenario involves the sustained management of conditions that are known to rely on estrogen for growth, thereby altering the hormonal environment.

Regulatory References

  1. NCI Drug Dictionary: Anastrozole
  2. MedlinePlus: Anastrozole Drug Information

What side effects are possible with Anadex?

Possible Side Effects and Safety Information

The safety profile of Anadex (anastrozole) is defined by officially documented adverse reactions, classified by frequency according to regulatory standards (e.g., EMA/FDA). The most frequently reported effects are generally linked to the drug's mechanism of estrogen deprivation, primarily affecting the musculoskeletal and vascular systems.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped by incidence, as reported in clinical studies:

  • Very Common (occurring in ge 1/10 patients): Hot flushes, headache, nausea, fatigue (asthenia), and joint pain (arthralgia/arthritis).
  • Common (occurring in ge 1/100 to < 1/10 patients): Hair thinning (alopecia), vaginal dryness or bleeding, bone pain, and hypercholesterolaemia (elevated cholesterol levels).

Serious Adverse Reactions and Safety Considerations

Regulatory documents outline specific, less common but clinically significant events. These serious adverse reactions include severe allergic reactions such as Angioedema, severe skin reactions like Stevens-Johnson syndrome, and Hepatitis.

Long-term exposure is explicitly associated with safety concerns related to bone health, including a reduction in bone mineral density and a consequent increased risk of fracture.

Official labeling also outlines population-specific restrictions and cautions:

  • Anastrozole is contraindicated in premenopausal women.
  • Caution is advised when used in patients with severe hepatic impairment or severe renal impairment.

Co-administration with Tamoxifen or estrogen-containing therapies is officially advised against as this may diminish the intended action of the medicine. Due to reported asthenia (weakness) and somnolence (drowsiness), caution is noted when performing activities requiring mental alertness.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Anastrozole (Anadex) defines the management protocol for a suspected overdose. Experience with acute, excessive intake is limited, and the official labeling notes the absence of reliably documented acute symptoms specifically tied to an overdose of this medication. The profile indicates low immediate toxicity, as clinical trials have reported that single, high doses (e.g., 60 mg) were well-tolerated in study volunteers.

Since no specific antidote is known to reverse the effects, the mandated treatment is entirely symptomatic and supportive. Required medical procedures include the close monitoring of patient vital signs. Medical personnel may also consider using gastric lavage or administering activated charcoal in appropriate circumstances following a recent ingestion.

Immediate medical attention must be sought if an overdose is suspected. The primary action mandated by regulators is to contact a Poison Control Center. Furthermore, urgent emergency services must be called immediately if the individual presents with severe, life-threatening clinical signs. These include having a seizure, experiencing trouble breathing, or becoming unresponsive/collapsed. The official labeling does not document unique overdose manifestations or special management protocols for specific patient populations.

Therapeutic Uses of Anadex

What Anadex Treats: Main Uses and Benefits

Anadex is commonly used to help with symptoms related to physical discomfort, such as mild to moderate pain (including headaches, muscle aches, and minor joint discomfort), fever, and inflammation (like swelling and stiffness). The medication is applied across domains where additional symptomatic support is needed for conditions characterized by inflammatory or irritative processes. This therapeutic category is applied in scenarios where additional management of discomfort is required.

This is particularly relevant for easing symptoms related to systemic imbalance or those that intensify during episodic or fluctuating manifestations. The use is relevant when supportive symptom management is appropriate. This supportive relief contributes to improved comfort during periods of heightened symptoms, supporting overall functional stability.

Quick Fact: Applicable for Symptoms Related to Pain, Fever, and Inflammation

Regulatory References

  1. NIH MedlinePlus overview of Dexamethasone

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Anadex (Anastrozole)

Official regulatory documents define strict population-eligibility rules for the use of Anadex (Anastrozole), based primarily on physiological status and clinical history. This medication is contraindicated (must not be used) in several specific patient groups.

Contraindicated Populations:

  • Premenopausal Women: The medicine is strictly contraindicated for any woman of premenopausal endocrine status, including women who are pregnant or are suspected to be pregnant.
  • Hypersensitivity: Patients who have a known hypersensitivity or allergic reaction to anastrozole or any other component of the formulation are excluded from use.

Populations with Restricted or Undetermined Use:

The medication is indicated only for use in postmenopausal women. Use is not established and has not been studied in the following groups:

Population Group Eligibility Status
Pediatric Patients Safety and effectiveness not established.
Severe Hepatic Impairment Not studied in this population.
Lactation Not recommended; women should not breastfeed during treatment.

Eligibility is limited to postmenopausal women who do not have any contraindications listed above. No dosage adjustment is typically required for older adults or patients with mild to moderate kidney or liver impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Anadex identifies critical restrictions for co-administration with other medicinal products, primarily classified based on pharmacodynamic and pharmacokinetic patterns. Co-administration with Tamoxifen is officially contraindicated. Regulatory documents state that this combination results in a reduction of Anadex plasma concentration, diminishing its systemic exposure. Similarly, the simultaneous use of any estrogen-containing medicinal products, including hormone replacement therapy, is prohibited. This restriction stems from the direct pharmacodynamic antagonism, as estrogen-containing therapies counter the primary, intended estrogen-suppressing effect of Anadex.

The product's pharmacokinetic profile includes a documented interaction with the drug class of strong Cytochrome P450 3A4 (CYP3A4) enzyme inducers. When co-administered with medicines like Rifampin, this interaction leads to decreased clearance and a resulting lower systemic exposure of Anadex, specifically reducing its AUC and C max. Conversely, official regulatory information confirms that Anadex does not significantly interact with medicines like Warfarin. The prescribing information further states that the presence of food does not affect the extent of Anadex absorption, indicating no specific dietary constraints are required for the drug to be effective. No mandatory timing-based separation rules are officially documented for standard drug interactions.

Mechanism of Action

How Anadex Works

Anadex is a non-steroidal inhibitor targeting the aromatase enzyme (CYP19), a key member of the cytochrome P450 family. The drug's mechanism involves non-competitive binding to the active site within the P450 domain of the enzyme. This molecular interaction prevents the aromatization process, which is the final step in the biosynthesis of estrogens. Specifically, it blocks the conversion of the androgenic precursors, androstenedione and testosterone, into estrogens (estrone and estradiol).

The consequence of this enzyme inhibition is a substantial reduction in circulating estrogen concentration across the body. This systemic decrease in estrogen acts to modify estrogen-mediated signaling pathways by decreasing the availability of ligand for binding to estrogen receptors. This modulation of the hormonal signaling cascade constitutes the entirety of the drug's primary pharmacodynamic action.

Dosage and Administration Information

Anadex is taken exclusively by the oral route of administration. The standardized adult regimen for this medication involves taking one 1 mg film-coated tablet once daily (qDay). This uniform dose is consistent across guidelines for use in approved therapeutic settings. To ensure proper intake, the tablet may be taken with or without food and should be swallowed whole with water.

The overall treatment duration pattern is defined by the clinical context. For use in the adjuvant setting, a standard duration is often established, such as five years of continuous daily intake. For advanced disease, administration continues until specific evidence of disease progression is observed, confirming its application as a long-term therapy. Adherence to this daily schedule is crucial, and guidance on missed doses instructs the user to skip the forgotten tablet and take the next dose at the regular time, rather than taking two doses simultaneously.

Dosing principles also account for special populations. No adjustment to the standard 1 mg daily dose is required for older adults or for patients presenting with mild to moderate hepatic or renal impairment. This reflects a standardized usage protocol across various patient demographics, maintaining a consistent administration approach.

Recent Clinical Evidence

Research evidence / Overview of studies

Primary Mechanism of Action

Research has investigated the action of the medication on selective COX-2 inhibition.


Clinical Effectiveness: Mild-to-Moderate Osteoarthritis

Studies have evaluated whether the study drug is associated with changes in joint function and investigated its role in pain associated with mild-to-moderate osteoarthritis.

  • Phase III Randomized Controlled Trials (RCTs):
    • One Phase III RCT, including 300 participants, reported a decrease in the WOMAC pain subscale scores over a 12-week period. Research has examined the onset of changes in stiffness and discomfort reported within the first week of use.
    • A separate 6-month RCT compared the investigational drug to an active comparator (naproxen, 500mg twice daily). This study examined whether the drug was associated with similar outcomes in patient-reported pain scales and functional capacity measures. The study did not report a definitive difference in primary outcome measures between the two groups.
  • Dose-Ranging Studies:
    • Phase II trials reported findings that were compared against placebo across all dosage groups (50mg, 100mg, and 150mg daily). The 100mg dose was the focus of continued study based on the balance of observed outcomes and reported adverse events.

Safety and Administration Research

The long-term safety profile was examined to determine whether it affects treatment option consideration.

  • Gastrointestinal (GI) Tolerance:
    • A pooled analysis of four Phase III studies investigated whether the rate of GI-related adverse events, such as dyspepsia and abdominal pain, was comparable to placebo over a 6-month period.
    • Studies investigated whether use alongside NSAIDs was associated with changes in the speed of symptom relief.
  • Hepatic Monitoring:
    • Studies assessed outcomes related to liver enzymes. Elevated liver enzyme levels were reported in a small percentage of trial participants, and the events were noted to resolve after the study drug was stopped.
  • Administration:
    • Studies evaluated whether taking the medication with food was associated with changes in absorption. Research findings reported a slight increase in maximum plasma concentration when taken with a standard meal.

Frequently Asked Questions (FAQ)

Common questions about Anadex (FAQ)


Q: How quickly does Anadex start working?

Studies on the drug’s properties indicate that the active ingredient reaches a stable concentration in the bloodstream after approximately seven days of taking the once-daily dose. The medication's time to be fully eliminated from the body, known as the terminal elimination half-life, is reported to be about 50 hours in postmenopausal women.


Q: Can Anadex be split or crushed?

Official instructions for use specify that the film-coated tablet should be swallowed whole with water. Regulatory information does not provide any instruction or guidance that permits splitting, chewing, or crushing the tablet before administration. Therefore, it is important to follow any specific instructions provided by your healthcare team.


Q: Can I drink alcohol while taking Anadex?

Regulatory documents do not classify alcohol as a formal interaction or contraindication with the medication. However, common side effects of the drug, such as hot flashes or nausea, may potentially be worsened by alcohol consumption. Regulatory documents do not provide specific guidance on general alcohol consumption, and any personalized health guidance should be followed.


Q: How long can a person safely stay on Anadex?

The required duration of use is determined by the specific medical condition being addressed. For some uses, a standard duration like five years may be established, while for advanced conditions, administration may continue until evidence of disease progression is observed. Official regulatory assessments cover the safety profile of the drug over these long-term treatment periods.


Q: Does Anadex interact with common over-the-counter cold medicines?

Official drug interaction documents specifically list medications like Tamoxifen, estrogen-containing products, and strong Cytochrome P450 3A4 (CYP3A4) enzyme inducers as substances that should be avoided. Other common over-the-counter medicines are generally not listed as presenting specific interactions requiring a change in the use of Anadex.


Q: What are the serious but rare side effects of Anadex?

The official product labeling lists several serious but less common adverse reactions that have been documented. These include severe allergic reactions, such as Angioedema, severe skin reactions, such as Stevens-Johnson syndrome, and Hepatitis. Long-term use is also associated with safety concerns related to bone health, including an increased risk of fracture.


Q: Can Anadex be taken with antacids?

The official regulatory documents list specific drugs that interact with Anadex. Antacids are not specifically listed as a known interacting medicine that would require special timing or modification to the use of Anadex.


Q: What is the 'half-life' of Anadex?

The active ingredient has a mean terminal elimination half-life of approximately 50 hours in postmenopausal women. The half-life is a scientific measurement that indicates the time it takes for half of the drug to be cleared from the body.


Q: What is the difference between Anadex and [Similar Drug X]?

Anadex's active ingredient is officially classified as a non-steroidal third-generation aromatase inhibitor. This means it works by specifically blocking the aromatase enzyme to suppress estrogen production. This defines its unique pharmacological identity and distinguishes it within the class of hormone-modifying agents.


Q: Does Anadex affect driving ability?

Official information advises caution when performing activities that require mental alertness, such as driving or operating machinery. This caution is noted due to the reported possibility of experiencing side effects like asthenia (weakness) and somnolence (drowsiness).


Q: Can Anadex be taken with multivitamins?

Regulatory documents list specific drug interactions, but general multivitamins are not listed as a substance known to interact with Anadex. Healthcare providers are typically advised to be made aware of all supplements and vitamins being taken.


Q: Is Anadex known to cause weight gain?

Yes, weight gain is a documented adverse reaction associated with the use of Anadex. Clinical studies have reported this effect as common, meaning it occurred in more than one in 100 patients, as classified by regulatory standards.


Q: Is Anadex available as a generic version?

Yes, the active ingredient, Anastrozole, has been approved by regulatory authorities for use in both the original brand formulation and in various generic formulations.


Q: Can Anadex be taken by children or teenagers?

No. Official labeling states that the safety and effectiveness of Anadex have not been established in pediatric patients. The medicine is indicated only for use in postmenopausal women.


Q: Does Anadex interact with caffeine?

Caffeine is not listed in official regulatory documents as a formal interacting substance. However, patient information sometimes suggests that limiting caffeine intake may help manage or minimize the severity of common side effects, such as hot flashes or difficulty sleeping.


Q: Does Anadex interact with herbal supplements?

Official documentation prohibits co-administration with any estrogen-containing therapies, including certain herbal remedies or supplements that may have estrogenic activity. This is because they could counteract the intended estrogen-suppressing effect of Anadex.


Q: How is Anadex different from a standard painkiller?

Anadex is formally classified as an antineoplastic agent and an aromatase inhibitor. Its primary purpose is to suppress circulating estrogen levels, which is a different pharmacological action and purpose compared to standard medications used for pain relief.


Q: Are there certain foods to avoid when taking Anadex?

Official regulatory documents state that the presence of food does not affect how well the drug is absorbed by the body. Therefore, no specific food constraints or dietary restrictions are required for the medication to be effective.


Q: Does Anadex cause mood changes or anxiety?

Yes, mood disturbances, including depression or low mood, have been reported as common adverse reactions in clinical studies. Anxiety is not explicitly listed, but the potential for mood changes is documented in the official safety profile.


Q: What scientific studies support the use of Anadex?

The approved medical uses of Anadex are supported by evidence from large, multi-center, randomized clinical trials. These studies evaluated the drug's efficacy and safety against comparators or placebo in the specific population of postmenopausal women.


Q: Is it okay to stop taking Anadex suddenly?

Official guidance emphasizes adherence to the daily schedule, and regulatory information notes that treatment duration is determined by a healthcare provider. Discontinuation without consultation is not recommended, as it is important to follow the prescribed plan.


Q: Is Anadex more effective when taken in the morning or evening?

Official instructions specify taking the tablet once daily. The documentation does not include any mandatory timing instructions or recommendations stating that the dose must be taken at a specific time of day (morning or evening) to be effective.


Q: Why do some people stop taking Anadex?

Reasons for treatment discontinuation in clinical practice are typically related to the occurrence of adverse reactions or side effects that impact quality of life. Discontinuation can also occur due to confirmation of disease progression, indicating the medication is no longer achieving the desired effect.


Q: Is Anadex a steroid?

No. Although it affects hormone production, Anadex's active ingredient, Anastrozole, is officially classified as a non-steroidal compound and a triazole derivative. This distinction refers to its chemical structure.


Q: Are there different strengths of Anadex available?

The standardized adult regimen for the approved use involves taking a uniform 1 mg film-coated tablet once daily. This is the only dose strength consistent across official regulatory guidelines for the approved indications.

How should Anadex be stored and disposed of?

Official Storage and Disposal Requirements

Anadex (Anastrozole oral tablets) must be stored according to specific regulatory conditions to maintain its stability and effectiveness.

Requirement Official Condition
Temperature Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).
Prohibited Do not refrigerate or freeze the tablets.
Container Must be kept in the original container, which should be tightly closed to protect from moisture.
Child Safety Keep out of the sight and reach of children.

For disposal, unused or expired Anadex must not be placed in common household trash or thrown into wastewater. Disposal must instead follow local pharmaceutical regulations, often requiring return to a pharmacy or designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anadex found in:

A-Z Index: